HUE037270T2 - Biokémiailag stabilizált HIV-1 ENV trimer vakcina - Google Patents

Biokémiailag stabilizált HIV-1 ENV trimer vakcina

Info

Publication number: HUE037270T2
Authority: HU; Hungary
Prior art keywords: env trimer; stabilized hiv; vaccine; biochemically; biochemically stabilized
Prior art date: 2008-10-10

Application number

HUE09820044A

Other languages

English (en)

Inventor

Stephen Harrison

Bing Chen

Dan Barouch

Joseph Nkolola

Michael Seaman

Original Assignee

Childrens Medical Center

Beth Israel Deaconess Medical Ct Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-10-10

Filing date

2009-10-13

Publication date

2018-08-28

2009-10-13 Application filed by Childrens Medical Center, Beth Israel Deaconess Medical Ct Inc filed Critical Childrens Medical Center

2018-08-28 Publication of HUE037270T2 publication Critical patent/HUE037270T2/hu

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16051—Methods of production or purification of viral material
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16171—Demonstrated in vivo effect

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Virology (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Microbiology (AREA)
Genetics & Genomics (AREA)
Mycology (AREA)
Epidemiology (AREA)
Biochemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Communicable Diseases (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Hematology (AREA)
Gastroenterology & Hepatology (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
General Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
Oncology (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

HUE09820044A 2008-10-10 2009-10-13 Biokémiailag stabilizált HIV-1 ENV trimer vakcina HUE037270T2 (hu)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US10444908P	2008-10-10	2008-10-10

Publications (1)

Publication Number	Publication Date
HUE037270T2 true HUE037270T2 (hu)	2018-08-28

Family

ID=42101262

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
HUE09820044A HUE037270T2 (hu)	2008-10-10	2009-10-13	Biokémiailag stabilizált HIV-1 ENV trimer vakcina
HUE18150843A HUE049393T2 (hu)	2008-10-10	2009-10-13	Biokémiailag stabilizált HIV-1 ENV trimer vakcina

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
HUE18150843A HUE049393T2 (hu)	2008-10-10	2009-10-13	Biokémiailag stabilizált HIV-1 ENV trimer vakcina

Country Status (14)

Country	Link
US (6)	US9707289B2 (hu)
EP (2)	EP3335728B8 (hu)
AU (1)	AU2009303284B2 (hu)
CY (2)	CY1119921T1 (hu)
DK (2)	DK3335728T3 (hu)
ES (2)	ES2765890T3 (hu)
HR (2)	HRP20180281T1 (hu)
HU (2)	HUE037270T2 (hu)
LT (2)	LT2340038T (hu)
PL (2)	PL3335728T3 (hu)
PT (2)	PT2340038T (hu)
SI (2)	SI2340038T1 (hu)
TR (1)	TR201802130T4 (hu)
WO (1)	WO2010042942A2 (hu)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1868651A4 (en)	2005-04-12	2010-10-06	Univ Duke	METHOD FOR INDUCING ANTIBODIES THAT NEUTRALIZE THE HUMAN IMMUNODEFICIENCY VIRUS
WO2008127651A1 (en)	2007-04-13	2008-10-23	Duke University	Method of inducing neutralizing antibodies to human immunodeficiency virus
US20120070488A1 (en) *	2007-09-28	2012-03-22	Duke University	Method of inducing neutralizing antibodies to human immunodeficiency virus
HUE037270T2 (hu)	2008-10-10	2018-08-28	Childrens Medical Center	Biokémiailag stabilizált HIV-1 ENV trimer vakcina
AU2010232915A1 (en)	2009-04-03	2011-10-20	Duke University	Formulation for inducing broadly reactive neutralizing anti-HIV antibodies
US9060984B2 (en) *	2010-10-30	2015-06-23	George Dacai Liu	Recombinant HIV-1 envelope proteins comprising stabilizing two-cysteine mini-domains in gp41
US20130302366A1 (en) *	2012-05-09	2013-11-14	Christopher Marshall	Conformationally Specific Viral Immunogens
WO2014022475A2 (en) *	2012-08-03	2014-02-06	Dana-Faber Cancer Institute, Inc.	Compositions and methods for conformationally stabilizing primate immunodeficiency virus envelope glycoprotein trimers
JP6357487B2 (ja) *	2013-01-07	2018-07-11	ベスイスラエルデアコネスメディカルセンターインコーポレイテッド	安定化ヒト免疫不全ウイルス（ｈｉｖ）エンベロープ（ｅｎｖ）トリマーワクチン及びそれを使用する方法
AU2014224049B2 (en)	2013-02-28	2018-11-29	Therabiol, Inc.	HIV antigens and antibodies
US9675687B2 (en)	2013-03-15	2017-06-13	University Of Massachusetts	Compositions and methods to treat AIDS
WO2015048635A1 (en)	2013-09-27	2015-04-02	Duke University	Mper-liposome conjugates and uses thereof
DK3052518T3 (da)	2013-10-04	2020-04-06	Beth Israel Deaconess Medical Ct Inc	Stabiliserede humant immundefektvirus-(hiv)-klade c-kappe-(env)-trimer-vacciner og fremgangsmåder til anvendelse deraf
NZ728072A (en)	2014-07-11	2018-06-29	Gilead Sciences Inc	Modulators of toll-like receptors for the treatment of hiv
MY175620A (en)	2014-09-26	2020-07-02	Beth Israel Deaconess Medical Ct Inc	Methods and compositions for inducing protective immunity against human immunodeficiency virus infection
WO2016196471A1 (en)	2015-06-02	2016-12-08	Cooper Human Systems Llc	Methods and compositions for treatment of hiv infection
BR112018011122A2 (pt)	2015-12-15	2018-11-21	Janssen Vaccines & Prevention B.V.	antígenos, vetores, composições, e métodos de utilização para o vírus da imunodeficiência humana dos mesmos
JP6595132B2 (ja)	2016-06-16	2019-10-23	ヤンセンファッシンズアンドプリベンションベーフェー	Ｈｉｖワクチン製剤
CN110494159A (zh)	2016-09-02	2019-11-22	扬森疫苗与预防公司	在接受抗逆转录病毒治疗的对象中诱导针对人类免疫缺陷病毒感染的免疫应答的方法
HUE052008T2 (hu)	2016-09-15	2021-04-28	Janssen Vaccines & Prevention Bv	Trimert stabilizáló HIV-burokfehérje-mutációk
WO2018075559A1 (en)	2016-10-17	2018-04-26	Beth Israel Deaconess Medical Center, Inc.	Signature-based human immunodeficiency virus (hiv) envelope (env) trimer vaccines and methods of using the same
EA202090049A1 (ru)	2017-06-15	2020-04-15	Янссен Вэксинс Энд Превеншн Б.В.	Поксвирусные векторы, кодирующие антигены вич, и способы их применения
BR112020000867A2 (pt)	2017-07-19	2020-07-21	Janssen Vaccines & Prevention B.V.	mutações da proteína do envelope do hiv estabilizando o trímero
US20190022212A1 (en)	2017-07-21	2019-01-24	Beth Israel Deaconess Medical Center, Inc.	Methods for safe induction of cross-clade immunity against human immunodeficiency virus infection in human
WO2019055888A1 (en)	2017-09-18	2019-03-21	Janssen Vaccines & Prevention B.V.	METHODS OF INDUCING AN IMMUNE RESPONSE AGAINST HUMAN IMMUNODEFICIENCY VIRUS INFECTION IN SUBJECTS UNDER ANTIRETROVIRAL TREATMENT
US11517618B2 (en)	2018-09-25	2022-12-06	Janssen Vaccines & Prevention B.V.	Method of inducing an immune response against human immunodeficiency virus by co-localized administration of vaccine components
WO2020237052A1 (en)	2019-05-22	2020-11-26	Janssen Vaccines & Prevention B.V.	Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment
AU2020381082B2 (en)	2019-11-07	2022-09-22	Janssen Vaccines & Prevention B.V.	Protein purification
WO2023198815A1 (en)	2022-04-14	2023-10-19	Janssen Vaccines & Prevention B.V.	Sequential administration of adenoviruses

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4603112A (en)	1981-12-24	1986-07-29	Health Research, Incorporated	Modified vaccinia virus
US4522811A (en)	1982-07-08	1985-06-11	Syntex (U.S.A.) Inc.	Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
JPS6147500A (ja)	1984-08-15	1986-03-07	Res Dev Corp Of Japan	キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en)	1984-08-27	1987-11-25	The Board Of Trustees Of The Leland Stanford Junior University	Chimeric receptors by dna splicing and expression
GB8422238D0 (en)	1984-09-03	1984-10-10	Neuberger M S	Chimeric proteins
JPS61134325A (ja)	1984-12-04	1986-06-21	Teijin Ltd	ハイブリツド抗体遺伝子の発現方法
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
ATE141646T1 (de)	1986-04-09	1996-09-15	Genzyme Corp	Genetisch transformierte tiere, die ein gewünschtes protein in milch absondern
US4873316A (en)	1987-06-23	1989-10-10	Biogen, Inc.	Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5223409A (en)	1988-09-02	1993-06-29	Protein Engineering Corp.	Directed evolution of novel binding proteins
CA1340288C (en)	1988-09-02	1998-12-29	Robert Charles Ladner	Generation and selection of novel binding proteins
US5750373A (en)	1990-12-03	1998-05-12	Genentech, Inc.	Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants
US5298416A (en)	1989-01-18	1994-03-29	British Technology Group Ltd.	Attenuated polioviruses
US5328470A (en)	1989-03-31	1994-07-12	The Regents Of The University Of Michigan	Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5427908A (en)	1990-05-01	1995-06-27	Affymax Technologies N.V.	Recombinant library screening methods
GB9015198D0 (en)	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance
ES2139598T3 (es)	1990-07-10	2000-02-16	Medical Res Council	Procedimientos para la produccion de miembros de parejas de union especifica.
DK1279731T3 (da)	1991-03-01	2007-09-24	Dyax Corp	Fremgangsmåde til udvikling af bindende miniproteiner
EP1471142B1 (en)	1991-04-10	2008-11-19	The Scripps Research Institute	Heterodimeric receptor libraries using phagemids
DE4122599C2 (de)	1991-07-08	1993-11-11	Deutsches Krebsforsch	Phagemid zum Screenen von Antikörpern
US5505947A (en)	1994-05-27	1996-04-09	The University Of North Carolina At Chapel Hill	Attenuating mutations in Venezuelan Equine Encephalitis virus
US6710173B1 (en)	1999-06-25	2004-03-23	Progenics Pharmaceuticals, Inc.	Stabilized viral envelope proteins and uses thereof
CA2384271A1 (en) *	1999-09-17	2001-03-22	Joseph G. Sodroski	Stabilized soluble glycoprotein trimers
AU2003291402A1 (en)	2002-11-07	2004-06-03	Beth Israel Deaconess Medical Center	MIP-1Alpha AND GM-CSF AS ADJUVANTS OF IMMUNE RESPONSE
CA2505583C (en) *	2002-12-03	2014-07-15	University Of Massachusetts	Polyvalent, primary hiv-1 glycoprotein dna vaccines and vaccination methods
US20070298051A1 (en)	2003-11-19	2007-12-27	Beth Israel Deaconess Medical Center	Adjuvants Of Immune Response
WO2006002079A2 (en) *	2004-06-15	2006-01-05	Progenics Pharmaceuticals, Inc.	Hiv-1 neutralizing antibodies elicited by trimeric hiv-1 envelope glycoprotein complex
JP4772045B2 (ja) *	2004-07-16	2011-09-14	アメリカ合衆国	Ｃｍｖ／ｒ核酸コンストラクトを含むａｉｄｓに対するワクチン
MX2007004188A (es)	2004-10-13	2007-10-11	Crucell Holland Bv	Vectores adenovirales mejorados y usos de los mismos.
CA2656741A1 (en) *	2005-07-06	2007-01-11	University Of Maryland Biotechnology Institute	Constrained hiv envelope-based immunogen that simultaneously presents receptor and coreceptor binding sites
WO2007024941A2 (en)	2005-08-23	2007-03-01	The Regents Of The University Of California	Polyvalent vaccine
US20100143302A1 (en)	2006-03-16	2010-06-10	Crucell Holland B.V.	Recombinant Adenoviruses Based on Serotype 26 and 48, and Use Thereof
US20110076298A1 (en)	2006-06-19	2011-03-31	Olson William C	Soluble stabilized trimeric hiv env proteins and uses thereof
WO2008063331A2 (en) *	2006-10-23	2008-05-29	Progenics Pharmaceuticals, Inc.	Modified gp140 envelope polypeptides of hiv-1 isolates, compositions, stabilized trimeric complexes, and uses thereof
HUE037270T2 (hu)	2008-10-10	2018-08-28	Childrens Medical Center	Biokémiailag stabilizált HIV-1 ENV trimer vakcina
NZ602504A (en)	2008-11-18	2014-01-31	Beth Israel Hospital	Antiviral vaccines with improved cellular immunogenicity
IT1395574B1 (it)	2009-09-14	2012-10-16	Guala Dispensing Spa	Dispositivo di erogazione
SI3556396T1 (sl)	2010-08-31	2022-09-30	Theraclone Sciences, Inc.	Nevtralizacijska protitelesa proti virusu človeške imunske pomanjkljivosti (HIV)
US20140348791A1 (en)	2011-09-09	2014-11-27	Beth Israel Deaconess Medical Center, Inc.	Modified adenoviral vectors and methods of treatment using same
CA2789539A1 (en)	2011-09-12	2013-03-12	International Aids Vaccine Initiative	Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
EP2766037A4 (en)	2011-10-12	2015-08-05	Scripps Research Inst	HIV-1 GP-120 MINI-V3 LOOP AND USES THEREOF
US9683268B2 (en)	2012-09-19	2017-06-20	Beth Israel Deaconess	Viruses associated with immunodeficiency and enteropathy and methods using same
CN105051198A (zh)	2012-11-16	2015-11-11	貝丝以色列女执事医疗中心	重组腺病毒及其用途
JP6357487B2 (ja)	2013-01-07	2018-07-11	ベスイスラエルデアコネスメディカルセンターインコーポレイテッド	安定化ヒト免疫不全ウイルス（ｈｉｖ）エンベロープ（ｅｎｖ）トリマーワクチン及びそれを使用する方法
RU2698049C2 (ru) *	2013-07-08	2019-08-21	Новартис Аг	Ротавирусные частицы с химерными поверхностными белками
EP3052132B1 (en)	2013-09-30	2020-07-29	Beth Israel Deaconess Medical Center, Inc.	Antibody therapies for human immunodeficiency virus (hiv)
US10444908B2 (en)	2016-12-31	2019-10-15	Innoventions, Inc.	Virtual touchpads for wearable and portable devices

2009
- 2009-10-13 HU HUE09820044A patent/HUE037270T2/hu unknown
- 2009-10-13 EP EP18150843.3A patent/EP3335728B8/en active Active
- 2009-10-13 SI SI200931800T patent/SI2340038T1/en unknown
- 2009-10-13 LT LTEP09820044.7T patent/LT2340038T/lt unknown
- 2009-10-13 WO PCT/US2009/060494 patent/WO2010042942A2/en active Application Filing
- 2009-10-13 DK DK18150843.3T patent/DK3335728T3/da active
- 2009-10-13 AU AU2009303284A patent/AU2009303284B2/en not_active Ceased
- 2009-10-13 HU HUE18150843A patent/HUE049393T2/hu unknown
- 2009-10-13 SI SI200932027T patent/SI3335728T1/sl unknown
- 2009-10-13 PL PL18150843T patent/PL3335728T3/pl unknown
- 2009-10-13 TR TR2018/02130T patent/TR201802130T4/tr unknown
- 2009-10-13 ES ES18150843T patent/ES2765890T3/es active Active
- 2009-10-13 DK DK09820044.7T patent/DK2340038T3/en active
- 2009-10-13 EP EP09820044.7A patent/EP2340038B1/en active Active
- 2009-10-13 PT PT98200447T patent/PT2340038T/pt unknown
- 2009-10-13 LT LTEP18150843.3T patent/LT3335728T/lt unknown
- 2009-10-13 PL PL09820044T patent/PL2340038T3/pl unknown
- 2009-10-13 ES ES09820044.7T patent/ES2659875T3/es active Active
- 2009-10-13 PT PT181508433T patent/PT3335728T/pt unknown
2011
- 2011-04-08 US US13/082,601 patent/US9707289B2/en active Active
2017
- 2017-05-16 US US15/596,312 patent/US9950060B2/en active Active
2018
- 2018-02-15 HR HRP20180281TT patent/HRP20180281T1/hr unknown
- 2018-02-15 CY CY20181100190T patent/CY1119921T1/el unknown
- 2018-03-13 US US15/919,834 patent/US10307478B2/en active Active
2019
- 2019-04-16 US US16/385,438 patent/US10463729B2/en not_active Expired - Fee Related
- 2019-09-23 US US16/579,025 patent/US10653770B2/en not_active Expired - Fee Related
2020
- 2020-01-23 CY CY20201100062T patent/CY1122745T1/el unknown
- 2020-03-04 HR HRP20200370TT patent/HRP20200370T1/hr unknown
- 2020-04-27 US US16/858,808 patent/US11229696B2/en active Active

Also Published As

Publication number	Publication date
AU2009303284A1 (en)	2010-04-15
LT3335728T (lt)	2020-03-10
US20180207259A1 (en)	2018-07-26
US20170290907A1 (en)	2017-10-12
US10653770B2 (en)	2020-05-19
US20190240319A1 (en)	2019-08-08
DK3335728T3 (da)	2020-02-24
US10463729B2 (en)	2019-11-05
US11229696B2 (en)	2022-01-25
EP2340038A4 (en)	2012-08-15
US9707289B2 (en)	2017-07-18
TR201802130T4 (tr)	2018-03-21
ES2765890T3 (es)	2020-06-11
HUE049393T2 (hu)	2020-09-28
LT2340038T (lt)	2018-04-10
US20200323976A1 (en)	2020-10-15
US10307478B2 (en)	2019-06-04
WO2010042942A3 (en)	2010-06-24
HRP20180281T1 (hr)	2018-05-04
CY1119921T1 (el)	2018-12-12
EP3335728B1 (en)	2019-12-25
HRP20200370T1 (hr)	2020-06-12
US9950060B2 (en)	2018-04-24
PL2340038T3 (pl)	2018-07-31
SI3335728T1 (sl)	2020-04-30
ES2659875T3 (es)	2018-03-19
US20200023056A1 (en)	2020-01-23
EP2340038A2 (en)	2011-07-06
US20120045472A1 (en)	2012-02-23
PL3335728T3 (pl)	2020-06-29
PT3335728T (pt)	2020-02-19
WO2010042942A2 (en)	2010-04-15
EP3335728B8 (en)	2020-03-11
CY1122745T1 (el)	2021-01-27
DK2340038T3 (en)	2018-02-26
EP2340038B1 (en)	2018-01-10
AU2009303284B2 (en)	2016-01-28
PT2340038T (pt)	2018-02-21
SI2340038T1 (en)	2018-05-31
EP3335728A1 (en)	2018-06-20

Publication	Publication Date	Title
SI3335728T1 (sl)	2020-04-30	Biokemično stabilizirano HIV-1 ENV trimer cepivo
IL217008A0 (en)	2012-02-29	Vaccine
GB0810305D0 (en)	2008-07-09	Influenza vaccination
HRP20151124T1 (en)	2015-11-20	Vaccine
PL2358386T3 (pl)	2017-04-28	Zoptymalizowane szczepionki na grypę
IL222228A0 (en)	2012-12-31	Hiv vaccine
GB0822001D0 (en)	2009-01-07	Vaccine
IL212311A0 (en)	2011-06-30	Immunoenhancer-linked oligomeric hiv vaccines
EP2588211A4 (en)	2014-03-05	EPS TRIMER-IMMUNOGENIC
GB0810710D0 (en)	2008-07-16	Vaccine
GB201006165D0 (en)	2010-05-26	Vaccine
GB0918679D0 (en)	2009-12-09	Influenza vaccine
GB0816284D0 (en)	2008-10-15	Vaccine
ZA201100962B (en)	2012-05-30	Influenza vaccines
IL216102A0 (en)	2012-01-31	Combined measles-malaria vaccine
GB0816447D0 (en)	2008-10-15	Vaccine
GB201000522D0 (en)	2010-03-03	Vaccine
EP2424879A4 (en)	2013-06-05	INFLUENZA VACCINE
IL217194A0 (en)	2012-02-29	Vaccine
EP2240199A4 (en)	2012-10-03	INFLUENZA VACCINES
ZA201107971B (en)	2012-07-25	Combined measles-malaria vaccine
GB0914545D0 (en)	2009-09-30	Vaccine
AP2010005295A0 (en)	2010-06-30	Vaccine
GB0806461D0 (en)	2008-05-14	Anti-atheroma vaccine
GB0809781D0 (en)	2008-07-09	Vaccine